Blocking immunosurveillance of B‐cell lymphoma and myeloma via CD4 T cell is a suggestive pathophysiological pathway due to the increased risk of cancer in long‐term use of fingolimod in patients.8 Here, CD4 is linked to B-cell non-Hodgkin lymphoma.